Diagnostics (Sep 2023)

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking

  • Aikaterini Tsantikidi,
  • Eirini Papadopoulou,
  • Vasiliki Metaxa-Mariatou,
  • George Kapetsis,
  • Georgios Tsaousis,
  • Angeliki Meintani,
  • Chrysiida Florou-Chatzigiannidou,
  • Maria Gazouli,
  • Christos Papadimitriou,
  • Eleni Timotheadou,
  • Athanasios Kotsakis,
  • Anastasios Boutis,
  • Ioannis Boukovinas,
  • Eleftherios Kampletsas,
  • Loukas Kontovinis,
  • Elena Fountzilas,
  • Charalampos Andreadis,
  • Charisios Karanikiotis,
  • Dimitrios Filippou,
  • Georgios Theodoropoulos,
  • Mustafa Özdoğan,
  • George Nasioulas

DOI
https://doi.org/10.3390/diagnostics13182962
Journal volume & issue
Vol. 13, no. 18
p. 2962

Abstract

Read online

Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The BRCA1/2 genes and mutations in many additional genes involved in the HR pathway may be responsible for the HRD phenomenon. The aim of the present study was to investigate the association between genomic loss of heterozygosity (gLOH) and alterations in 513 genes with targeted and immuno-oncology therapies in 406 samples using an NGS assay. In addition, the %gLOHs of 24 samples were calculated using the Affymetrix technology in order to compare the results obtained via the two methodologies. HR variations occurred in 20.93% of the malignancies, while BRCA1/2 gene alterations occurred in 5.17% of the malignancies. The %LOH was highly correlated with alterations in the BRCA1/2 genes, since 76.19% (16/21) of the BRCA1/2 positive tumors had a high %LOH value (p = 0.007). Moreover, the LOH status was highly correlated with the TP53 and KRAS statuses, but there was no association with the TMB value. Lin’s concordance correlation coefficient for the 24 samples simultaneously examined via both assays was 0.87, indicating a nearly perfect agreement. In conclusion, the addition of gLOH analysis could assist in the detection of additional patients eligible for treatment with PARPis.

Keywords